Your browser is no longer supported. Please, upgrade your browser.
Assembly Biosciences, Inc.
Index- P/E- EPS (ttm)-1.78 Insider Own0.60% Shs Outstand35.19M Perf Week-2.46%
Market Cap153.13M Forward P/E- EPS next Y-2.96 Insider Trans-0.56% Shs Float31.49M Perf Month-8.55%
Income-62.20M PEG- EPS next Q-0.79 Inst Own68.50% Short Float15.44% Perf Quarter-37.04%
Sales79.10M P/S1.94 EPS this Y52.80% Inst Trans0.21% Short Ratio4.29 Perf Half Y-25.98%
Book/sh6.84 P/B0.58 EPS next Y7.50% ROA-20.80% Target Price- Perf Year-78.66%
Cash/sh5.60 P/C0.71 EPS next 5Y17.00% ROE-24.10% 52W Range3.81 - 27.84 Perf YTD-34.55%
Dividend- P/FCF- EPS past 5Y0.60% ROI- 52W High-85.78% Beta0.34
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low3.94% ATR0.19
Employees139 Current Ratio9.20 Sales Q/Q-79.20% Oper. Margin-81.90% RSI (14)39.91 Volatility5.52% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.70% Profit Margin-78.60% Rel Volume0.57 Prev Close3.89
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.13M Price3.96
Recom2.00 SMA20-4.47% SMA50-10.65% SMA200-60.00% Volume650,344 Change1.80%
Mar-23-21Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-20Downgrade Jefferies Buy → Hold $30 → $10
Oct-19-20Initiated Truist Buy $55
Oct-16-19Initiated Mizuho Buy $20
Nov-19-18Initiated Leerink Partners Outperform $45
Oct-08-18Upgrade B. Riley FBR Neutral → Buy $42
Aug-08-18Initiated Robert W. Baird Outperform $74
Apr-13-18Downgrade Chardan Capital Markets Buy → Neutral $35 → $50
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $35
Nov-08-17Initiated Jefferies Buy $50
May-30-17Initiated Chardan Capital Markets Buy $35
May-07-21 05:00PM  
May-06-21 08:35PM  
Apr-29-21 05:03PM  
Apr-27-21 06:39AM  
Mar-05-21 05:00PM  
Mar-04-21 10:01PM  
Feb-26-21 11:52AM  
Feb-25-21 07:10PM  
Feb-19-21 08:00AM  
Feb-18-21 11:38PM  
Feb-08-21 10:11AM  
Feb-05-21 05:00PM  
Dec-19-20 04:45PM  
Dec-15-20 11:32PM  
Dec-08-20 04:02PM  
Dec-04-20 04:30PM  
Nov-17-20 08:00AM  
Nov-16-20 08:00AM  
Nov-13-20 08:00AM  
Nov-06-20 04:41PM  
Nov-05-20 05:15PM  
Nov-02-20 08:00AM  
Oct-29-20 12:35PM  
Oct-20-20 08:00AM  
Oct-15-20 08:00AM  
Oct-13-20 01:14PM  
Oct-05-20 07:30AM  
Oct-02-20 04:30PM  
Sep-17-20 07:23AM  
Sep-04-20 04:30PM  
Aug-28-20 06:00AM  
Aug-27-20 08:00AM  
Aug-07-20 04:30PM  
Aug-05-20 07:55PM  
Jul-27-20 11:42PM  
Jul-20-20 07:53AM  
Jul-09-20 08:00AM  
Jul-02-20 04:30PM  
Jun-25-20 08:00AM  
Jun-24-20 08:55AM  
Jun-23-20 11:42AM  
Jun-22-20 08:45AM  
Jun-19-20 07:41AM  
Jun-18-20 04:01PM  
Jun-01-20 04:18PM  
May-27-20 08:00AM  
May-26-20 08:00AM  
May-19-20 04:05PM  
May-15-20 11:14AM  
May-13-20 10:58AM  
May-07-20 04:05PM  
May-06-20 06:33AM  
May-04-20 08:00AM  
May-01-20 05:00PM  
Apr-30-20 04:05PM  
Apr-06-20 08:00AM  
Mar-31-20 04:05PM  
Mar-30-20 08:00AM  
Mar-04-20 06:05PM  
Feb-20-20 12:31PM  
Feb-19-20 08:00AM  
Jan-28-20 06:00AM  
Dec-16-19 04:05PM  
Dec-12-19 06:30AM  
Dec-11-19 04:03PM  
Dec-10-19 11:11AM  
Dec-06-19 08:00AM  
Nov-18-19 08:00AM  
Nov-11-19 08:00AM  
Nov-08-19 04:13PM  
Nov-07-19 05:30PM  
Nov-06-19 04:40PM  
Oct-31-19 10:47AM  
Oct-30-19 06:58AM  
Oct-28-19 05:15PM  
Oct-18-19 11:02AM  
Oct-17-19 04:27PM  
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Papkoff Jacqueline SybilSVP-CSO MicrobiomeDec 14Sale6.151,2977,98337,364Dec 15 09:18 PM
Stamm Luisa MChief Medical OfficerNov 09Sale5.104,39722,4047,603Nov 10 07:28 PM
McHutchison John GCEO and PresidentAug 07Sale21.8012,151264,917137,849Aug 10 04:34 PM